Hence, like anti-CD137 mAb, anti-GITR mAb, and other GITR-targeting therapies have the potential to boost the effectiveness of current cancer therapies by virtue of pro-inflammatory and cytotoxic effects involving NK cells. The gene discussed is TNFRSF18; the disease is cancer.